Progress in imaging the effects of psychosis susceptibility gene variants.

Abstract:

:Genetic imaging has become an increasingly popular tool that utilizes neuroimaging techniques to investigate the impact of genetic variation on the structure, function and connectivity of the brain. Combining genetic and neuroimaging domains is a promising approach to further the understanding of the neural mechanisms involved in mediating the effect of genetic variants on psychosis risk, with the potential to explore individual vulnerability to psychiatric illness. Imaging genetics approaches have successfully been applied to a wide range of risk genes for schizophrenia. This article reviews the recent literature on genetic imaging in schizophrenia, using two key susceptibility genes for psychosis, DISC1 and NRG1, as examples. The authors explore challenges and future perspectives in the field, including the need for future research to focus on epistatic effects of multiple common variants, account for the complexity of gene-environment interactions, characterize rare high-risk structural variants and identify more effective neuroimaging paradigms that reach a higher threshold of heritability. Ultimately, this review highlights that genetic imaging remains a research technique, and further progress and integration with other techniques will be required before we can predict the onset and development of schizophrenia.

journal_name

Expert Rev Neurother

authors

Redpath HL,Lawrie SM,Sprooten E,Whalley HC,McIntosh AM,Hall J

doi

10.1586/ern.12.145

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

37-47

issue

1

eissn

1473-7175

issn

1744-8360

journal_volume

13

pub_type

杂志文章,评审
  • Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder.

    abstract::Initial descriptions of bipolar disorder (BD) emphasized that patients returned to a baseline condition after acute episodes. Such definitions were operational in teasing bipolar disorder apart from schizophrenia, where patients were described to be permanently impaired after the initial episodes. However, this view o...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.7.1101

    authors: Kapczinski F,Frey BN,Kauer-Sant'Anna M,Grassi-Oliveira R

    更新日期:2008-07-01 00:00:00

  • Novel therapeutic strategies using nanodrug delivery, stem cells and combination therapy for CNS trauma and neurodegenerative disorders.

    abstract::The 10th Global College of Neuroprotection and Neuroregeneration Annual Conference in collaboration with the 6th International Association of Neurorestoratology VI Intercontinental Hotel, Bucharest, Romania, 4-7 April 2013 The 10th Global College of Neuroproetction and Neuroregeneration Annual Conference together with...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2013.836297

    authors: Sharma HS,Muresanu DF,Sharma A

    更新日期:2013-10-01 00:00:00

  • The search for biomarkers in Parkinson's disease: a critical review.

    abstract::Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily presents with features of bradykinesia, rigidity and tremor, and has, as part of its core pathology, the degeneration of dopaminergic neurons in the substantia nigra pars compacta. There is a great need for the development of a reliabl...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.12.1841

    authors: Antoniades CA,Barker RA

    更新日期:2008-12-01 00:00:00

  • NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.

    abstract::Since we last addressed the roles of NF-κB and JAK/STAT3 signaling in glioblastoma (GBM) 5 years ago, tremendous strides have been made in the understanding of these two pathways in glioma biology. Contributing to prosurvival mechanisms, cancer stem cell maintenance and treatment resistance, both NF-κB and STAT3 have ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.964211

    authors: Gray GK,McFarland BC,Nozell SE,Benveniste EN

    更新日期:2014-11-01 00:00:00

  • Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.

    abstract::Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/ern.09.68

    authors: Naoi M,Maruyama W

    更新日期:2009-08-01 00:00:00

  • Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis.

    abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). The modern treatment era for MS witnessed a growing pool of drugs now available for use in clinical practice. These therapies work at different levels, however there is a lack of treatments acting on the neurode...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1378098

    authors: Ruggieri S,Tortorella C,Gasperini C

    更新日期:2017-11-01 00:00:00

  • Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies.

    abstract:INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1194203

    authors: Amanatkar HR,Papagiannopoulos B,Grossberg GT

    更新日期:2017-01-01 00:00:00

  • Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis?

    abstract::Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple scle...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.111

    authors: Dennison L,Moss-Morris R

    更新日期:2010-09-01 00:00:00

  • Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression.

    abstract::According to the corticoid receptor hypothesis of depression, hyperactivity of the hypothalamic-pituitary-adrenocortical (HPA) system is one of the major pathophysiological factors for the development of depression and opens a broad range of new antidepressant treatment options that are related to direct interventions...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/ern.09.52

    authors: Schüle C,Baghai TC,Eser D,Rupprecht R

    更新日期:2009-07-01 00:00:00

  • Deep brain stimulation for the treatment of uncommon tremor syndromes.

    abstract:INTRODUCTION:Deep brain stimulation (DBS) has become a standard therapy for the treatment of select cases of medication refractory essential tremor and Parkinson's disease however the effectiveness and long-term outcomes of DBS in other uncommon and complex tremor syndromes has not been well established. Traditionally,...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1194756

    authors: Ramirez-Zamora A,Okun MS

    更新日期:2016-08-01 00:00:00

  • Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses.

    abstract::Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric condition that affects approximately 5.3% of children worldwide. This disorder is defined by a combination of symptoms of inattention and hyperactivity/impulsivity. Diagnosis is based on impairment in these two domains determining several problems...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.17

    authors: Genro JP,Kieling C,Rohde LA,Hutz MH

    更新日期:2010-04-01 00:00:00

  • Epilepsy in the elderly.

    abstract::Epilepsy is the most common serious neurological disorder in the elderly after stroke and dementia. It may be more important for elderly people because it is intermittent and unpredictable. There is no reliable diagnostic test and so its diagnosis and management requires clinical acumen and experience. The situation i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.170

    authors: Johnston A,Smith PE

    更新日期:2010-12-01 00:00:00

  • Cannabinoids as potential new therapy for the treatment of gliomas.

    abstract::Gliomas constitute the most frequent and malignant primary brain tumors. Current standard therapeutic strategies (surgery, radiotherapy and chemotherapeutics, e.g., temozolomide, carmustin or carboplatin) for their treatment are only palliative and survival diagnosis is normally 6-12 months. The development of new the...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.1.37

    authors: Parolaro D,Massi P

    更新日期:2008-01-01 00:00:00

  • Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.

    abstract::Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative disorder, causes cognitive decline and has a devastating effect on the quality of life. AD occurs mainly through abnormal amyloid β peptide (Aβ) and tau protein (tau) activity around/in neurons. Aβ-based therapeutic techniques have been s...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1621750

    authors: Kuo YC,Rajesh R

    更新日期:2019-07-01 00:00:00

  • Translational pain biomarkers in the early development of new neurotherapeutics for pain management.

    abstract::Translation of the analgesic efficacy of investigational neurotherapeutics from pre-clinical pain models into clinical trial phases is associated with a high risk of failure. Application of human pain biomarkers in early stages of clinical trials can potentially enhance the rate of successful translation, which would ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.884925

    authors: Arendt-Nielsen L,Nielsen TA,Gazerani P

    更新日期:2014-03-01 00:00:00

  • Zonisamide: newer antiepileptic agent with multiple mechanisms of action.

    abstract::Zonisamide (Zonegran, Eisai, Inc.) is a broad spectrum antiepileptic drug indicated for use as adjunctive therapy in the treatment of partial seizures. Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disord...

    journal_title:Expert review of neurotherapeutics

    pub_type: 历史文章,杂志文章,评审

    doi:10.1586/14737175.4.6.935

    authors: Biton V

    更新日期:2004-11-01 00:00:00

  • Sumatriptan/naproxen sodium combination for the treatment of migraine.

    abstract::Sumatriptan 85 mg with naproxen sodium 500 mg, a combination tablet for the acute treatment of migraine, is approved in the USA. It is likely that triptan/NSAID combination benefits are a class effect, although the majority of data are on sumatriptan and naproxen sodium. The combination tablet demonstrated superior ef...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.9.1289

    authors: Cleves C,Tepper SJ

    更新日期:2008-09-01 00:00:00

  • Precision medicine in genetic epilepsies: break of dawn?

    abstract:INTRODUCTION:Therapy with current antiepileptic drugs aims at reducing the likelihood of seizure occurrence rather than influencing the underlying disease process. Therefore, antiepileptic drugs have an anticonvulsant rather than antiepileptic property. Areas covered: The increasing identification of genetic causes for...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1253476

    authors: Reif PS,Tsai MH,Helbig I,Rosenow F,Klein KM

    更新日期:2017-04-01 00:00:00

  • Trigeminal neuralgia and persistent idiopathic facial pain.

    abstract::Trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) are two of the most puzzling orofacial pain conditions and affected patients are often very difficult to treat. TN is characterized by paroxysms of brief but severe pain followed by asymptomatic periods without pain. In some patients a constant dul...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.156

    authors: Obermann M,Holle D,Katsarava Z

    更新日期:2011-11-01 00:00:00

  • Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.

    abstract::Alzheimer's disease (AD) is the most common CNS disorder occurring worldwide. There is neither proven effective prevention for AD nor a cure for patients with this disorder. Hence, there is an urgent need to develop safer and more efficacious drugs to help combat the tremendous increase in disease progression. The pre...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.988709

    authors: Prakash A,Kalra J,Mani V,Ramasamy K,Majeed AB

    更新日期:2015-01-01 00:00:00

  • Stroke in systemic lupus erythematosus.

    abstract::With improved control of the immunological phenomena of systemic lupus erythematosus, the epidemiology of this disease is changing. While both cardiac and neurological manifestations of systemic lupus erythematosus have been consistently described, there is increasing awareness of the need for general cardiovascular p...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.3.385

    authors: Wierzbicki AS

    更新日期:2002-05-01 00:00:00

  • Response of gait deficits to neuromuscular electrical stimulation for stroke survivors.

    abstract::Persistent gait deficits after stroke can cause falls, elevated energy cost and poor endurance. Coordination impairment is an underlying cause of gait deficits. Few efficacious interventions have been described that have targeted and measured restoration of coordinated gait components. Neuromuscular electrical stimula...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.10.1511

    authors: Daly JJ

    更新日期:2006-10-01 00:00:00

  • Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision.

    abstract::With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.3.357

    authors: Bergamaschi R

    更新日期:2006-03-01 00:00:00

  • Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.

    abstract:INTRODUCTION:Calcitonin Gene-Related Peptide (CGRP) has gradually emerged as a suitable therapeutic target to treat migraine. Considering the social and economic burden of migraine, it is fundamental to optimize the disease management with efficacious and safe treatments. In this scenario, drugs targeting GCRP, monoclo...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1772758

    authors: De Matteis E,Guglielmetti M,Ornello R,Spuntarelli V,Martelletti P,Sacco S

    更新日期:2020-06-01 00:00:00

  • Treating multiple sclerosis with monoclonal antibodies: a 2013 update.

    abstract::The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the years 2010-2012. The natalizumab section gives a progressive multifocal leukoencephalopathy update, focusing on clinically relevant aspects. Furthermore, it outlines problems around natalizum...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.13.17

    authors: Deiß A,Brecht I,Haarmann A,Buttmann M

    更新日期:2013-03-01 00:00:00

  • Update on therapies for cluster headache.

    abstract::Cluster headache is one of the primary headache disorders. It is considered the most severe headache syndrome known to humans. In most instances, this disorder is readily treatable when the correct medications are utilized at the correct dosages. Cluster headache treatment involves abortive, transitional and preventiv...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.3.295

    authors: Rozen TD

    更新日期:2002-05-01 00:00:00

  • Recent genetic advances in ADHD and diagnostic and therapeutic prospects.

    abstract::Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.4.453

    authors: Hawi Z,Kirley A,Lowe N,Fitzgerald M,Gill M

    更新日期:2003-07-01 00:00:00

  • Craniomandibular muscles, intraoral orthoses and migraine.

    abstract::Intraoral splints are effective in migraine prevention. In this review, changes in the quality of life of migraineurs treated with a palatal nonoccluding splint were measured. Using the Migraine Specific Quality of Life Instrument (Version 2.1), it was found that the palatal nonoccluding splint significantly improved ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.3.371

    authors: Shevel E

    更新日期:2005-05-01 00:00:00

  • Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease.

    abstract::With increasing life expectancy, the early diagnosis and treatment of Alzheimer's disease has become critical in sustaining a healthy society. Noninvasive markers of disease progression starting from the earliest stages of pathologic involvement are required for determining the effectiveness of putative disease-modify...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.5.663

    authors: Kantarci K

    更新日期:2005-09-01 00:00:00

  • Menstrual migraine: clinical and therapeutical aspects.

    abstract::Estrogens fluctuations, particularly their premenstrual fall, are currently regarded as the main triggers of menstrual migraine (MM). MM presents in two clinical forms: pure MM, where attacks are confined to the perimenstrual period (PMP), and menstrually related migraine, where attacks always occur during, but are no...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.9.1105

    authors: Allais G,Castagnoli Gabellari I,De Lorenzo C,Mana O,Benedetto C

    更新日期:2007-09-01 00:00:00